<DOC>
	<DOCNO>NCT00777309</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double blind phase 2 study design compare treatment ARQ 197 plus erlotinib erlotinib plus placebo patient non-small cell lung cancer . The study enroll patient one prior chemotherapy regimen ( erlotinib ) NSCLC .</brief_summary>
	<brief_title>A Randomized Phase 2 Study Erlotinib + ARQ 197 Versus Erlotinib + Placebo Previously Treated Patients With Locally Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This randomize , placebo-controlled , double blind phase 2 study design compare treatment ARQ 197 plus erlotinib erlotinib plus placebo patient non-small cell lung cancer . The study enroll patient one prior chemotherapy regimen ( erlotinib ) NSCLC . The study evaluate progression-free survival two arm . A total 154 patient enrol .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Provide sign date informed consent prior studyspecific screening procedure 2 . ≥ 18 year old 3 . Histologically cytologically confirm inoperable locally advanced metastatic ( stage IIIB/IV ) NSCLC 4 . ≥ one prior chemotherapy regimen ( include adjuvant chemotherapy ) ( include erlotinib EGFR inhibit agent ) 5 . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 7 . Male female patient childproducing potential must agree use double barrier contraception , oral contraceptive avoidance pregnancy measure study 90 day last day treatment 8 . Females childbearing potential must negative serum pregnancy test 9 . Good organ function 10 . Confirmed availability archival pathology sample ( 10 unstained paraffinembedded slide ) tissue block suitable subsequent analysis KRAS , EGFR , cMet 1 . Previous receipt erlotinib EGFR inhibit therapy 2 . Receipt antitumor treatment NSCLC within 4 week ( 2 week radiotherapy ) prior start designate treatment 3 . Documented major surgical procedure within 4 week prior randomization . 4 . Symptomatic central nervous system metastases either consider opinion investigator clinically unstable require steroid , antiepileptic , symptomrelieving medication 5 . Pregnant , breastfeeding , refuse double barrier contraception , oral contraceptive avoidance pregnancy measure 6 . Significant gastrointestinal disorder , opinion Investigator , could interfere absorption ARQ 197 and/or erlotinib ( e.g . Crohn 's disease , small large bowel resection , malabsorbtion syndrome ) 7 . Unable unwilling swallow complete dose erlotinib ARQ 197 8 . Any known contraindication treatment ARQ 197 erlotinib 9 . Any known hypersensitivity component ARQ 197 erlotinib 10 . Other malignancy within 5 year randomization , exception adequately treat intraepithelial carcinoma cervix uterus , prostate carcinoma PSA value &lt; 0.2 ng/ml basal squamous cell carcinoma skin 11 . Previously diagnose grade 3 4 ( CTCAE ) bradycardia heart arrhythmia 12 . Any significant comormid condition , opinion Investigator , would impair study participation cooperation 13 . Known human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>NSCLC</keyword>
</DOC>